

## Supply Notice

At Novo Nordisk, we understand that our medicines are critically important to you. As part of our commitment to sharing timely and transparent information, we want to provide you with an important update about the NovoSeven® RT (Coagulation Factor VIIa, Recombinant) 8 mg vial.

Due to supply constraints, Novo Nordisk will be unable to provide the 8 mg vial of NovoSeven® RT from January until mid-2024. Importantly, the overall supply of NovoSeven® RT is expected to remain intact as other vial sizes are available as a solution for those who would otherwise use the 8 mg vial. Patients can use the 1 mg, 2 mg, and 5 mg vials in combination to make the dose they need in absence of the 8 mg vial. If you have questions about how to make up your dose, please consult your healthcare provider.

This is not a quality issue. Novo Nordisk has decided to temporarily limit supply of the 8 mg vial because it requires the highest amount of Active Pharmaceutical Ingredient (API), which is currently constrained, compared to the other vial sizes. By re-directing the API towards the 1 mg, 2 mg, and 5 mg vial sizes, we can produce more and help ensure the overall supply of NovoSeven® RT remains intact for patients. Again, we don't expect constraints on supply of the 1 mg, 2 mg, and 5 mg vials that would impact availability for patients.

We recognize the inconvenience this may cause you, and we are working hard to restore availability of the 8 mg vial as soon as possible. We are in dialogue with HCPs, advocacy groups, specialty pharmacies, and specialty distributors to minimize the impact this will have on patients.

We thank you for your patience and will continue to share updates as they become available. In the interim, if you have any questions, please reach out to your healthcare provider, your Novo Nordisk Community Liaison, or contact Novo Care customer support at 1-844-668-6732.

**Please [click here](#) for Prescribing Information, including Boxed Warning.**

You can find out who your Novo Nordisk Community Liaison is by clicking [HERE](#).

Sincerely,

Novo Nordisk

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088.

The information in this email is for information purposes only and is not promotional or intended to replace a discussion with your healthcare provider.

NovoSeven® RT is a registered trademark of Novo Nordisk Health Care AG.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2023 Novo Nordisk All rights reserved.

US23NSVN00076 December 2023

